Emergent BioSolutions Inc. (EBS) Revenue History
Annual and quarterly revenue from 2001 to present
EBS Revenue Over Time (2001–2025)
EBS Revenue Growth History
15 of 22 years with positive growth- FY2001 revenue growth
- N/A
- FY2004 revenue growth
- +84.3%
- FY2005 revenue growth
- +56.5%
- FY2006 revenue growth
- +16.9%
- FY2007 revenue growth
- +19.8%
- FY2008 revenue growth
- -2.4%
- FY2009 revenue growth
- +31.5%
- FY2010 revenue growth
- +21.9%
- FY2011 revenue growth
- -4.5%
- FY2012 revenue growth
- +3.1%
- FY2013 revenue growth
- +10.9%
- FY2014 revenue growth
- +29.3%
- FY2015 revenue growth
- +21.0%
- FY2016 revenue growth
- -0.1%
- FY2017 revenue growth
- +14.8%
- FY2018 revenue growth
- +39.5%
- FY2019 revenue growth
- +41.4%
- FY2020 revenue growth
- +42.6%
- FY2021 revenue growth
- +12.4%
- FY2022 revenue growth
- -37.0%
- FY2023 revenue growth
- -6.1%
- FY2024 revenue growth
- -0.5%
- FY2025 revenue growth
- -28.8%
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $148.7M | -23.6% |
| Q3 2025 | $231.1M | -21.3% |
| Q2 2025 | $140.9M | -44.7% |
| Q1 2025 | $222.2M | -26.0% |
| Q4 2024 | $194.7M | -29.6% |
| Q3 2024 | $293.8M | +8.6% |
| Q2 2024 | $254.7M | -24.6% |
| Q1 2024 | $300.4M | +82.8% |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown (FY 2025)
EBS's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
EBS Revenue Analysis (2001–2025)
Current Revenue & Growth
As of June 22, 2026, Emergent BioSolutions Inc. (EBS) generated trailing twelve-month (TTM) revenue of $742.9 million, reflecting significant decline in growth of -23.6% year-over-year. The most recent quarter (Q4 2025) recorded $148.7 million in revenue, down 35.7% sequentially.
Historical Growth Trajectory
EBS's 5-year compound annual growth rate (CAGR) stands at -14.0%, indicating revenue contraction over this period. The 3-year CAGR of -12.7% exceeds the 5-year average, indicating an acceleration in the most recent period. Emergent BioSolutions Inc.'s highest annual revenue of $1.77 billion was recorded in 2021.
Revenue by Segment
EBS's revenue is primarily driven by Product (95%), and Contracts and Grants (5%). With over half of revenue concentrated in Product, the company has a focused business model while developing other growth vectors.
Peer Comparison
Compared to Healthcare sector peers — including SIGA (-22.1% YoY), PRGO (-3.6% YoY), and BRKR (+0.4% YoY) — EBS has underperformed the peer group in revenue growth. Compare EBS vs SIGA →
EBS Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| EBSCurrent | $743M | -23.6% | -14.0% | 14.8% | |
 SIGA | $95M | -22.1% | -5.4% | 25.1% | |
 PRGO | $4.3B | -3.6% | +0.8% | 8.1% | |
 BRKR | $3.4B | +0.4% | +11.6% | 6.9% | |
 ABCL | $75M | +242.7% | -20.3% | -289.0% | |
 PCRX | $726M | +4.6% | +11.1% | 4.6% |
EBS Historical Revenue Data (2001–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $742.9M | -28.8% | $350.6M | 47.2% | $110.2M | 14.8% |
| 2024 | $1.04B | -0.5% | $375.4M | 36.0% | $-108,700,000 | -10.4% |
| 2023 | $1.05B | -6.1% | $360.0M | 34.3% | $-726,400,000 | -69.2% |
| 2022 | $1.12B | -37.0% | $473.0M | 42.3% | $-170,000,000 | -15.2% |
| 2021 | $1.77B | +12.4% | $793.2M | 44.7% | $341.4M | 19.2% |
| 2020 | $1.58B | +42.6% | $863.1M | 54.7% | $438.5M | 27.8% |
| 2019 | $1.11B | +41.4% | $483.1M | 43.7% | $114.1M | 10.3% |
| 2018 | $782.4M | +39.5% | $320.4M | 41.0% | $89.8M | 11.5% |
| 2017 | $560.9M | +14.8% | $283.6M | 50.6% | $124.3M | 22.2% |
| 2016 | $488.8M | -0.1% | $244.8M | 50.1% | $105.5M | 21.6% |
| 2015 | $489.3M | +21.0% | $272.5M | 55.7% | $141.5M | 28.9% |
| 2014 | $404.5M | +29.3% | $197.8M | 48.9% | $89.2M | 22.1% |
| 2013 | $312.7M | +10.9% | $130.7M | 41.8% | $42.8M | 13.7% |
| 2012 | $281.9M | +3.1% | $112.6M | 39.9% | $36.6M | 13.0% |
| 2011 | $273.4M | -4.5% | $231.2M | 84.6% | $32.1M | 11.7% |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
25+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
EBS — Frequently Asked Questions
Quick answers to the most common questions about buying EBS stock.
Is EBS's revenue growth accelerating or slowing?
EBS revenue is declining -23.6% year-over-year. TTM revenue fell to $743M, contrasting with the 5-year CAGR of -14.0%. The reversal reflects either macro headwinds or company-specific challenges.
What is EBS's revenue history from 2001 to 2026?
Emergent BioSolutions Inc. (EBS) revenue history spans 2001 to 2026. TTM revenue as of 2026 is $743M, growing at -23.6% YoY. The 5-year CAGR is -14.0%. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is EBS's long-term revenue growth rate (CAGR)?
Emergent BioSolutions Inc.'s 5-year revenue CAGR of -14.0% reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of -23.6% is below this long-term average. CAGR is the most reliable measure of sustained revenue momentum for EBS.
Why does EBS's quarterly revenue fluctuate?
EBS quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Emergent BioSolutions Inc.'s revenue data from 2001 to 2026 shows full historical quarterly detail on this page.
How is EBS's revenue distributed by segment?
EBS reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does EBS's revenue compare to industry peers?
Emergent BioSolutions Inc. (EBS) with TTM revenue of $743M and -23.6% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.